[{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Undisclosed","graph2":"Phase III","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Rulonilimab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minodronic Acid","moa":"Farnesyl diphosphate synthase","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Valsartan","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Isosorbide","moa":"Soluble guanylate cyclase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Huazhi Rougan","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase IV","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Huazhi Rougan","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Granules","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Beijing Tongren Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lunan Pharmaceutical \/ Beijing Tongren Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Lunan Pharmaceutical \/ Beijing Tongren Hospital"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Rulonilimab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mosapride Citrate","moa":"5-HT4 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vonorasan Fumarate","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"F520","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"F520","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"F520","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"F520","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"F520","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Humanized anti-PD-1 Monoclonal Antibody","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"F520","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"F182112","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"F527","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Fudan University | Shanghai General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"XZ120","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lunan Pharmaceutical \/ Fudan University | Shanghai General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Lunan Pharmaceutical \/ Fudan University | Shanghai General Hospital"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LNF1901","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lunan Pharmaceutical \/ Sun Yat-sen University","highestDevelopmentStatusID":"6","companyTruncated":"Lunan Pharmaceutical \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LNF2007","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lunan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Lunan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Wuxi People\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lunan Pharmaceutical \/ Wuxi People\u2019s Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Lunan Pharmaceutical \/ Wuxi People\u2019s Hospital"}]
Find Clinical Drug Pipeline Developments & Deals by Lunan Pharmaceutical
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
